Travere Q1 net loss $86.3M; FILSPARI launch nets $3M in 6 weeks

Travere Therapeutics, Inc.

2023-Q1 EPS reported -$1.27 revenue$56,993,000

Net product sales $50.3M (incl. $3M FILSPARI), up from $46.4M YoY; net loss $86.3M ($1.27/share) vs $76M ($1.20).
Cash $561.5M after $216M stock offering and $23M milestone to Ligand for FILSPARI approval.
FILSPARI launched week of Feb 27; 146 new patient start forms received in first 6 weeks.
Phase 3 DUPLEX in FSGS missed primary eGFR slope endpoint; company to engage regulators on path forward.
EMA decision on sparsentan for IgAN expected H2 2023; PROTECT confirmatory data due Q4 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Travere Therapeutics, Inc. reported the quarter ended March 31, 2023 results: revenue $57.0 million, net income $86.3 million, EPS $1.27 per basic share.

Period: the quarter ended March 31, 2023
Revenue: $57.0 million
Net income: $86.3 million
EPS: $1.27 per basic share
Result: reported results

Exact text from the filing

IgAN in Europe expected in second half 2023 • Net product sales of FILSPARI totaled $3.0 million for the first quarter of 2023 • Total revenue for the first quarter of 2023 was $57.0 million, consisting of $50.3 million in net product sales and $6.7 million in licensing and collaboration revenue • Cash, cash equivalents, and marketable securities, as of March 31,

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

Travere Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001438533-23-000023

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.